AUTHOR=Zhu Cuifang , Li Ruofan , Ju Mingliang , Xiao Xudong , Yuan Ti-Fei , Jin Zhixing , Zhao Jing 

TITLE=Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial

JOURNAL=Frontiers in Molecular Neuroscience

VOLUME=15

YEAR=2022

URL=https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.892477

DOI=10.3389/fnmol.2022.892477

ISSN=1662-5099

ABSTRACT=<sec><title>Objective</title><p>To evaluate the efficacy and safety of metformin in the treatment of amisulpride-induced hyperprolactinemia.</p></sec><sec><title>Methods</title><p>A total of 86 schizophrenic patients who developed hyperprolactinemia after taking amisulpride were screened and randomly assigned to the metformin group (42 patients) and placebo group (44 patients) and followed up for eight weeks. The patients’ serum prolactin levels, blood glucose and lipids were measured at the baseline and the end of the intervention. The treatment emergent symptom scale (TESS) was also assessed.</p></sec><sec><title>Results</title><p>After eight weeks of intervention, serum prolactin levels in the metformin group decreased from (1737.360 ± 626.918) mIU/L at baseline to (1618.625 ± 640.865) mIU/L, whereas serum prolactin levels in the placebo group increased from (2676.470 ± 1269.234) mIU/L at baseline to (2860.933 ± 1317.376) mIU/L. There was a significant difference in prolactin changes (F<sup>covariance</sup> = 9.982, <italic>P</italic> = 0.002) between the two groups. There was no significant difference in the incidence of adverse drug reactions (<italic>P</italic> &gt; 0.05) between the two groups.</p></sec><sec><title>Conclusion</title><p>Metformin is able to improve amisulpride-induced hyperprolactinemia with its safety.</p></sec>